For: | Naqvi SMH, Gala MYN, Muchhala S, Arumugam A, Panigrahi D, Patil D, Rathod R, Mane A. Pharmacokinetics/Pharmacodynamics study of Fixtral SB as compared to supra bioavailable itraconazole and conventional itraconazole. World J Pharmacol 2023; 12(1): 1-11 [DOI: 10.5497/wjp.v12.i1.1] |
---|---|
URL: | https://www.wjgnet.com/2220-3192/full/v12/i1/1.htm |
Number | Citing Articles |
1 |
Dhiraj Dhoot. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison of a Single Dose of Super-bioavailable Itraconazole 130 mg and Innovator SUBA®-Itraconazole Capsules 130 mg (2 x 65 mg) in Healthy Adults Under Fed Conditions. Journal of Dermatology Research 2024; : 1 doi: 10.46889/JDR.2024.5204
|
2 |
Sucheta Singh, Meenakshi Kaira, Hrithik Dey, Kailash C. Pandey, Sumit Tahlan, Kuldeep Singh. Synthetic Methodology, SAR and Pharmacology of Commercialized Preparations Employing 1, 2, 4‐Triazole Analogues. ChemistrySelect 2024; 9(44) doi: 10.1002/slct.202404350
|